A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer
Latest Information Update: 20 Dec 2024
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Docetaxel (Primary) ; MK-4830 (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 29 Oct 2024 Status changed from active, no longer recruiting to completed.
- 20 Aug 2024 Planned End Date changed from 26 Dec 2024 to 25 Oct 2024.
- 17 Dec 2023 Planned End Date changed from 30 Dec 2024 to 26 Dec 2024.